Advertisement

AMAG Pharmaceuticals Inc. saw its stock jump almost 14 percent Monday, following news that the U.S. Food and Drug Administration will not slap a dreaded “black box” warning label on its drug to treat iron deficiency anemia. The drug, called Feraheme, has recently been the subject of scrutiny by the FDA, following reports of life-threatening hypersensitivity to the drug and instances of significant low blood pressure.

The Lexington-based company will, however, have to change its labeling on the intravenous treatment to reflect the seriousness of the risks.

SOURCE

Advertisement
Advertisement